Astria Therapeutics, Inc. (ATXS) Misses Q4 EPS by 3c

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q4 EPS of ($0.72), $0.03 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c